82_FR_7857 82 FR 7844 - National Institute on Drug Abuse; Notice of Meeting

82 FR 7844 - National Institute on Drug Abuse; Notice of Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 13 (January 23, 2017)

Page Range7844-7844
FR Document2017-01254

Federal Register, Volume 82 Issue 13 (Monday, January 23, 2017) 
[Federal Register Volume 82, Number 13 (Monday, January 23, 2017)]
[Notices]
[Page 7844]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-01254]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of a meeting of the 
National Advisory Council on Drug Abuse.
    The meeting will be open to the public as indicated below, with 
attendance limited to space available. Individuals who plan to attend 
and need special assistance, such as sign language interpretation or 
other reasonable accommodations, should notify the Contact Person 
listed below in advance of the meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and/or contract proposals 
and the discussions could disclose confidential trade secrets or 
commercial property such as patentable material, and personal 
information concerning individuals associated with the grant 
applications and/or contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Advisory Council on Drug Abuse.
    Date: February 15, 2017.
    Closed: 9:00 a.m. to 10:30 a.m.
    Agenda: To review and evaluate grant applications and/or 
proposals.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852.
    Open: 10:45 a.m. to 5:00 p.m.
    Agenda: This portion of the meeting will be open to the public 
for announcements and reports of administrative, legislative, and 
program developments in the drug abuse field.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852.
    Contact Person: Susan R.B. Weiss, Ph.D., Director, Division of 
Extramural Research, Office of the Director, National Institute on 
Drug Abuse, NIH, DHHS, 6001 Executive Boulevard, NSC, Room 5274, MSC 
9591, Rockville, MD 20892, 301-443-6487, [email protected].
    Any member of the public interested in presenting oral comments 
to the committee may notify the Contact Person listed on this notice 
at least 10 days in advance of the meeting. Interested individuals 
and representatives of organizations may submit a letter of intent, 
a brief description of the organization represented, and a short 
description of the oral presentation. Only one representative of an 
organization may be allowed to present oral comments and if accepted 
by the committee, presentations may be limited to five minutes. Both 
printed and electronic copies are requested for the record. In 
addition, any interested person may file written comments with the 
committee by forwarding their statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    Information is also available on the Institute's/Center's home 
page: www.drugabuse.gov/NACDA/NACDAHome.html, where an agenda and 
any additional information for the meeting will be posted when 
available.

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: January 13, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-01254 Filed 1-19-17; 8:45 am]
 BILLING CODE 4140-01-P

7844 Federal Register / Vol. 82, No. 13 / Monday, January 23, 2017 / Notices Contact Person: Neerja Kaushik-Basu, Dated: January 13, 2017. Any member of the public interested in Ph.D., Scientific Review Officer, Center for Anna Snouffer, presenting oral comments to the committee Scientific Review, National Institutes of may notify the Contact Person listed on this Deputy Director, Office of Federal Advisory Health, 6701 Rockledge Drive, Room 3198, notice at least 10 days in advance of the Committee Policy. MSC 7808, Bethesda, MD 20892, (301) 435– meeting. Interested individuals and 2306, kaushikbasun@csr.nih.gov. [FR Doc. 2017–01250 Filed 1–19–17; 8:45 am] representatives of organizations may submit Name of Committee: Center for Scientific BILLING CODE 4140–01–P a letter of intent, a brief description of the Review Special Emphasis Panel; Member organization represented, and a short Conflict: BTSS and SAT. description of the oral presentation. Only one Date: February 17, 2017. DEPARTMENT OF HEALTH AND representative of an organization may be Time: 1:00 p.m. to 5:00 p.m. HUMAN SERVICES allowed to present oral comments and if Agenda: To review and evaluate grant accepted by the committee, presentations applications. National Institutes of Health may be limited to five minutes. Both printed Place: National Institutes of Health, 6701 and electronic copies are requested for the Rockledge Drive, Bethesda, MD 20892 record. In addition, any interested person National Institute on Drug Abuse; (Virtual Meeting). may file written comments with the Notice of Meeting committee by forwarding their statement to Contact Person: Guo Feng Xu, Ph.D., Scientific Review Officer, Center for Pursuant to section 10(d) of the the Contact Person listed on this notice. The Scientific Review, National Institutes of statement should include the name, address, Federal Advisory Committee Act, as telephone number and when applicable, the Health, 6701 Rockledge Drive, Room 5122, MSC 7854, Bethesda, MD 20892, 301–237– amended (5 U.S.C. App.), notice is business or professional affiliation of the 9870, xuguofen@csr.nih.gov. hereby given of a meeting of the interested person. Name of Committee: Center for Scientific National Advisory Council on Drug Information is also available on the Abuse. Institute’s/Center’s home page: Review Special Emphasis Panel; The meeting will be open to the www.drugabuse.gov/NACDA/ Collaborative Applications: Child public as indicated below, with NACDAHome.html, where an agenda and Psychopathology. any additional information for the meeting Date: February 17, 2017. attendance limited to space available. will be posted when available. Time: 3:00 p.m. to 4:00 p.m. Individuals who plan to attend and Agenda: To review and evaluate grant (Catalogue of Federal Domestic Assistance need special assistance, such as sign Program Nos.: 93.279, Drug Abuse and applications. Place: Ritz-Carlton Hotel, 1700 Tysons language interpretation or other Addiction Research Programs, National Boulevard, McLean, VA 22102. reasonable accommodations, should Institutes of Health, HHS) Contact Person: Jane A Doussard- notify the Contact Person listed below Dated: January 13, 2017. Roosevelt, Ph.D., Scientific Review Officer, in advance of the meeting. Natasha M. Copeland, Center for Scientific Review, National The meeting will be closed to the Institutes of Health, 6701 Rockledge Drive, Program Analyst, Office of Federal Advisory public in accordance with the Committee Policy. Room 3184, MSC 7848, Bethesda, MD 20892, provisions set forth in sections (301) 435–4445, doussarj@csr.nih.gov. [FR Doc. 2017–01254 Filed 1–19–17; 8:45 am] 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Name of Committee: Center for Scientific as amended. The grant applications BILLING CODE 4140–01–P Review Special Emphasis Panel; PAR 16– 242: Bioengineering Research. and/or contract proposals and the Date: February 17, 2017. discussions could disclose confidential DEPARTMENT OF HEALTH AND Time: 4:00 p.m. to 5:00 p.m. trade secrets or commercial property HUMAN SERVICES Agenda: To review and evaluate grant such as patentable material, and applications. personal information concerning National Institutes of Health Place: The St. Regis Washington, DC, 923 individuals associated with the grant 16th Street NW., Washington, DC 20006. applications and/or contract proposals, National Institute of Allergy and Contact Person: Yvonne Bennett, Ph.D., Infectious Diseases; Notice of Closed the disclosure of which would Scientific Review Officer, Center for Scientific Review, National Institutes of constitute a clearly unwarranted Meeting Health, 6701 Rockledge Drive, Room 5199, invasion of personal privacy. Pursuant to section 10(d) of the MSC 7846, Bethesda, MD 20892, 301–379– Name of Committee: National Advisory Federal Advisory Committee Act, as 3793, bennetty@csr.nih.gov. Council on Drug Abuse. amended (5 U.S.C. App.), notice is Name of Committee: Center for Scientific Date: February 15, 2017. hereby given of the following meeting. Review Special Emphasis Panel; Closed: 9:00 a.m. to 10:30 a.m. The meeting will be closed to the Glycoscience Data Analysis Methods Agenda: To review and evaluate grant Glycoscience Data Analysis Methods. public in accordance with the applications and/or proposals. Date: February 17, 2017. Place: National Institutes of Health, provisions set forth in sections Time: 12:00 p.m. to 3:00 p.m. Neuroscience Center, 6001 Executive 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Agenda: To review and evaluate grant Boulevard, Rockville, MD 20852. as amended. The contract proposals and applications. Open: 10:45 a.m. to 5:00 p.m. the discussions could disclose Place: National Institutes of Health, 6701 Agenda: This portion of the meeting will confidential trade secrets or commercial Rockledge Drive, Bethesda, MD 20892 be open to the public for announcements and property such as patentable material, (Telephone Conference Call). reports of administrative, legislative, and and personal information concerning Contact Person: Raj K Krishnaraju, Ph.D., program developments in the drug abuse individuals associated with the contract Scientific Review Officer, Center for field. Scientific Review, National Institutes of proposals, the disclosure of which Place: National Institutes of Health, Health, 6701 Rockledge Drive, Room 6190, Neuroscience Center, 6001 Executive would constitute a clearly unwarranted mstockstill on DSK3G9T082PROD with NOTICES Bethesda, MD 20892, 301–435–1047, Boulevard, Rockville, MD 20852. invasion of personal privacy. kkrishna@csr.nih.gov. Contact Person: Susan R.B. Weiss, Ph.D., Name of Committee: National Institute of (Catalogue of Federal Domestic Assistance Director, Division of Extramural Research, Allergy and Infectious Diseases Special Program Nos. 93.306, Comparative Medicine; Office of the Director, National Institute on Emphasis Panel; NIAID Peer Review Meeting. 93.333, Clinical Research, 93.306, 93.333, Drug Abuse, NIH, DHHS, 6001 Executive Date: February 10, 2017. 93.337, 93.393–93.396, 93.837–93.844, Boulevard, NSC, Room 5274, MSC 9591, Time: 11:00 a.m. to 1:00 p.m. 93.846–93.878, 93.892, 93.893, National Rockville, MD 20892, 301–443–6487, Agenda: To review and evaluate contract Institutes of Health, HHS) sweiss@nida.nih.gov. proposals. VerDate Sep<11>2014 19:02 Jan 19, 2017 Jkt 241001 PO 00000 Frm 00062 Fmt 4703 Sfmt 4703 E:\FR\FM\23JAN1.SGM 23JAN1


Document Created: 2017-01-20 01:30:21
Document Modified: 2017-01-20 01:30:21
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
DatesFebruary 15, 2017.
FR Citation82 FR 7844 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR